EMA blocks products from one of Mercury Laboratories' plants in India

An EMA inspection team found big issues with a plant in India. (EMA)

India’s Mercury Laboratories intends to boost its exports but an EMA report shows regulators are not impressed with what the company is doing now.

A newly posted inspection report of one of Mercury’s plants in Jarod, India, found 20 deficiencies, including one critical and six major deficiencies. The plant is not currently shipping products to the European Union and the EMA said it shouldn’t be permitted to do so.

The critical deficiency was tied to authenticity of manufacturing records. Inspectors said production records and quality risk assessment records could not be verified.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The major deficiencies were related to poor manufacturing and process validation that does not assure that Mercury’s drugs consistently meet specifications and quality standards, the report said. There were also concerns about cross contamination.

The EMA has found similar issues with other Indian drugmaker, including some of the largest. A year ago, it found big issues at a Dr. Reddy’s small molecule tablet and capsule formulation facility in Bachupally Village, Telangana. Among other issues, the German inspection team raised questions over how the Dr. Reddy’s facility systematically invalidated out-of-specification testing results, claiming they were the result of "staff errors," yet providing no evidence of that.

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.